NCT02832700

Casein Glycomacropeptide in Healthy Subjects

Casein Glycomacropeptide in Healthy Subjects - Anti-inflammatory and Microbiome Modulating Effects

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: University of Aarhus · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent colitis and using human in vitro inflammation models. Its use as a food ingredient has proven safe and with no influence on dietary intake. In a pilot study the investigators found, that orally administered CGMP seems to have a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis. The investigators now wish to evaluate the effects in healthy subjects by studying the anti-inflammatory and microbiome modulating properties and by assessing possible changes in gastrointestinal symptoms.

Conditions

• Gastrointestinal Disease

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Casein glycomacropeptide
DIETARY_SUPPLEMENT	Placebo

Timeline

• Start date: 2016-06-01
• Primary completion: 2017-09-01
• Completion: 2017-09-01
• First posted: 2016-07-14
• Last updated: 2019-06-10

Locations

1 site across 1 country: Denmark